Nonmodifiable risk factors for DLB include age and family history. Risk increases substantially in individuals with a ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer ...

The chronic myeloid leukemia drug nilotinib (Tasigna) improved biomarkers and cognitive outcomes in people with dementia with Lewy bodies (DLB), a small phase II trial showed. In a study of 43 DLB ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia with Lewy bodies (DLB). This research, published in JAMA Neurology, could ...

A team discovered that patients with Dementia with Lewy Bodies (DLB) have significantly lower levels of α-synuclein in their blood compared to healthy individuals. This finding could lead to a ...

A research team has made a significant finding that sheds new light on dementia with Lewy Bodies (DLB). The team was led by Associate Professor Ayako Okado-Matsumoto from the Department of Biology ...

A research team led by Associate Professor Ayako Okado-Matsumoto from the Department of Biology at Toho University has made a significant finding that sheds new light on Dementia with Lewy Bodies ...

Dementia with lewy bodies (“DLB”) patients, treated with 200mg of nilotinib had statistically significant improvement in cognitive function compared to placebo. MCLEAN, VA, UNITED STATES, June ...

After witnessing my mum's cognitive decline and with dementia now the leading cause of death for Australian women, I can't ...

Lewy Body dementia is thought to be the third-most common form of dementia, ranking after Alzheimer's and vascular dementia.

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in Alzheimer’s & Dementia. Although DLB is the second most common ...